laurabbook@gmail.com

*March 2022* Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial FDA Grants Breakthrough Therapy Designation to DZD9008 for EGFR Exon20Ins-Positive NSCLC

*January 2022* Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations. Osimertinib (Tagrisso) was shown to be a durable treatment for patients with central nervous system (CNS) metastasis who had non-small…

*January 2022* Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. We conducted a systematic review to investigate the available data on this patients’ subgroup. Overall, we found a high heterogeneity in the incidence of compound mutations (4–26% of…

*January 2022* Highlights Clonal architecture of molecular alterations at the cellular level depicts cancer cell adaptation during targeted therapy. Single cell sequencing from patient biopsies revealed the co-existence of two driver alterations within single cancer cells. Pharmacological evaluation in patient derived models asserts the need of simultaneous inhibition of each driver. Read…

*January 2022* Two expert analyses appearing in the same issue of the Journal of Thoracic Oncology arrive at opposite conclusions regarding the value for metastatic non–small cell lung cancer (mNSCLC) of combining first-generation endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with either chemotherapy or vascular EGF (VEGF) monoclonal…

*February 2022* In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks with Dr. Zosia Piotrowska, Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital in Boston, Mass., about the current and future state of therapies for patients with EGFR mutant lung cancer. Listen here.

*December 2021* NEW YORK – Daiichi Sankyo and AstraZeneca on Thursday said that the first patient with HER2-mutant advanced non-small cell lung cancer has received treatment in a Phase III trial comparing their antibody-drug conjugate trastuzumab deruxtecan (Enhertu) against an immunotherapy-chemotherapy combination in the first-line setting. The DESTINY-Lung04 trial is evaluating trastuzumab…

*December 2021* Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to patritumab deruxtecan (HER3-DXd), a potential first-in-class HER3 directed antibody drug conjugate (ADC), for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC)…